awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q26863501-2D0BA73E-2BEE-433B-BB38-4A864CF40FF1
Q26863501-2D0BA73E-2BEE-433B-BB38-4A864CF40FF1
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26863501-2D0BA73E-2BEE-433B-BB38-4A864CF40FF1
Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising
P2860
Q26863501-2D0BA73E-2BEE-433B-BB38-4A864CF40FF1
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26863501-2D0BA73E-2BEE-433B-BB38-4A864CF40FF1
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
2eafcddf2eb6ab97e81ecbabbaa5400345961580
P2860
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer